Regeneron Gets CHMP Backing for Reduced Libtayo Dosing Schedule
Dow Jones2026/10/16 11:40By Colin Kellaher
Regeneron Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of a reduced dosing regimen for its blockbuster cancer drug Libtayo.
Regeneron on Friday said the CHMP recommendation supports reducing Libtayo's dosing frequency across all approved cancer types from every three weeks to every six weeks after the first 12 weeks of treatment.
The Tarrytown, N.Y., biotechnology company said the European Commission, which generally follows the CHMP's advice, is expected to announce a final decision in the coming months.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 16, 2026 07:40 ET (11:40 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.
Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.
Ripple Joins BlackRock, Standard Chartered in New Tokenization Report
Who is Satoshi Nakamoto? New Grok AI Study Tests Multiple Theories
Crypto prices
More
